| Experiments |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
Through its semiochemical chamber technology, Bioquark has
developed a proprietary methodology to stimulate, capture,
isolate, and standardize this real time, reprogramming
semiochemical language from living Xenopus eggs, and has
begun studying these bioactive materials pre-clinicaly for
therapeutic purposes.
The company has applied these semiochemical bioactives to
several discrete cell types, ex-vivo, to highlight the efficiency,
speed and versatility of these compounds for general human
tissue de-differentiation.
These cells, which in as rapidly as 24 hours, have all
exhibited strong pluripotency morphology and marker
expression (including Oct ¾, Nanog, Sox-2, TRA-1-60,
Rex-1, SSEA-1, SSEA-4, and alkaline phosphatase), have
included: BJ (Normal Foreskin Fibroblasts), HPA
(Pre-Adipocytes), Peripheral Blood CD4+Lymphocytes,
MCBC (Mononuclear Cord blood Cells), Buccal Mucosa Cells
(Squamous Epithelial Cells), and BMSC (Bone Marrow
Stromal Cells).
developed a proprietary methodology to stimulate, capture,
isolate, and standardize this real time, reprogramming
semiochemical language from living Xenopus eggs, and has
begun studying these bioactive materials pre-clinicaly for
therapeutic purposes.
The company has applied these semiochemical bioactives to
several discrete cell types, ex-vivo, to highlight the efficiency,
speed and versatility of these compounds for general human
tissue de-differentiation.
These cells, which in as rapidly as 24 hours, have all
exhibited strong pluripotency morphology and marker
expression (including Oct ¾, Nanog, Sox-2, TRA-1-60,
Rex-1, SSEA-1, SSEA-4, and alkaline phosphatase), have
included: BJ (Normal Foreskin Fibroblasts), HPA
(Pre-Adipocytes), Peripheral Blood CD4+Lymphocytes,
MCBC (Mononuclear Cord blood Cells), Buccal Mucosa Cells
(Squamous Epithelial Cells), and BMSC (Bone Marrow
Stromal Cells).
Importantly: in contrast to groups using ex-vivo nuclear
transfer, fusion, or genetic engineering (randomly
inserting combinations of virus-linked plutipotency genes
into human cells), all of which lead to an uncontrolled and
unstoppable journey into pluripotency, our semiochemical
strategy has provided us with a "biological on/off switch",
allowing detailed control of de-differentiation events at
various time points, stopping or starting the process at will.
Bioquark also spent time demonstrating the plasticity of these
de-differentiated cells by re-differentiating them via standard,
off-the-shelf protocols, into tissue representing the CNS
(neurons), with heart (cardiomyocytes) and liver
(hepatocytes) studies ongoing, highlighting control of fate in
a defined system.
transfer, fusion, or genetic engineering (randomly
inserting combinations of virus-linked plutipotency genes
into human cells), all of which lead to an uncontrolled and
unstoppable journey into pluripotency, our semiochemical
strategy has provided us with a "biological on/off switch",
allowing detailed control of de-differentiation events at
various time points, stopping or starting the process at will.
Bioquark also spent time demonstrating the plasticity of these
de-differentiated cells by re-differentiating them via standard,
off-the-shelf protocols, into tissue representing the CNS
(neurons), with heart (cardiomyocytes) and liver
(hepatocytes) studies ongoing, highlighting control of fate in
a defined system.
Lastly, Bioquark took the novel step of applying these unique
semiochemical bioactives to two diseased tissue types, HeLa
(Cervical Carcinoma Cells) and MCF-7 (Breast
Adenocarcinoma Cells), with a third cell type, Glioma cells
(Brain tumor) ongoing, to investigate what type of effects
would be seen in genetically damaged cells, in cases where
natural genetic control of proliferation had been lost. And this
is where the Bioquark team encountered results of additional
substantial interest: both of these cell types,
de-differentiated, but did not return to their cancerous,
uncontrolled growth patterns.
semiochemical bioactives to two diseased tissue types, HeLa
(Cervical Carcinoma Cells) and MCF-7 (Breast
Adenocarcinoma Cells), with a third cell type, Glioma cells
(Brain tumor) ongoing, to investigate what type of effects
would be seen in genetically damaged cells, in cases where
natural genetic control of proliferation had been lost. And this
is where the Bioquark team encountered results of additional
substantial interest: both of these cell types,
de-differentiated, but did not return to their cancerous,
uncontrolled growth patterns.
of direct pharmaceutical application of these bioactive
compounds for regeneration, but also in a unique approach to
natural reprogramming and repair.
Working off the fact that most chronic diseases, including
cancer, are associated with the effects of various genes,
lifestyle, environmental factors, and age-related DNA
damage, then targeted, in-vivo, de-differentiation and
re-differentiation can potentially lead to cellular
normalization, stability, and repair in many tissues.
Bioquark refers to its bioactive development agents as the
Bioquantines.
compounds for regeneration, but also in a unique approach to
natural reprogramming and repair.
Working off the fact that most chronic diseases, including
cancer, are associated with the effects of various genes,
lifestyle, environmental factors, and age-related DNA
damage, then targeted, in-vivo, de-differentiation and
re-differentiation can potentially lead to cellular
normalization, stability, and repair in many tissues.
Bioquark refers to its bioactive development agents as the
Bioquantines.
